Interpreting Trial Design and Toxicity Comparisons

John asks why neuropathy rates are similar and critiques Forward‑1 design choices, prior paclitaxel exposure, and comparator selection.

Play episode from 16:10

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!